Mangalam Retained Earnings from 2010 to 2024

MANGALAM   106.52  0.50  0.47%   
Mangalam Drugs' Retained Earnings are increasing over the years with slightly volatile fluctuation. Overall, Retained Earnings are expected to go to about 1 B this year. Retained Earnings is the cumulative amount of net income that Mangalam Drugs And retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals
 
Retained Earnings  
First Reported
2010-12-31
Previous Quarter
975.9 M
Current Value
B
Quarterly Volatility
434 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Mangalam Drugs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mangalam Drugs' main balance sheet or income statement drivers, such as Depreciation And Amortization of 153.8 M, Interest Expense of 146.1 M or Selling General Administrative of 410.2 M, as well as many indicators such as . Mangalam financial statements analysis is a perfect complement when working with Mangalam Drugs Valuation or Volatility modules.
  
This module can also supplement various Mangalam Drugs Technical models . Check out the analysis of Mangalam Drugs Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Mangalam Stock

Mangalam Drugs financial ratios help investors to determine whether Mangalam Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mangalam with respect to the benefits of owning Mangalam Drugs security.